{
    "ID": 30196,
    "ti        tle": "Will Bausch Health, Inc., file for bankruptcy before January 1, 2025?",
    "prompt": "QUESTION:\nWill Bausch Health, Inc., file for bankruptcy before January 1, 2025?\n\nTODAY'S DATE:\n2024-11-18\n\nRESOLUTION CRITERIA:\nThis question will resolve as **Yes** if Bausch Health, Inc., files any petition for bankruptcy protection in the United States, under any chapter of the United States Bankruptcy Code, before January 1, 2025. The question will resolves on the filing of such a petition, not on whether any bankruptcy protection is granted by a court. If no such petition is filed by that date, this question will resolve as **No**.\n\nBACKGROUND:\nBausch Health sells pharmaceutical drugs and medical devices. Recently it [denied](https://ir.bauschhealth.com/news-releases/2024/07-24-2024) it was considering bankruptcy, calling such reports \"unsubstantiated rumors.\"\n\nADDITIONAL BACKGROUND:\nTo assess the likelihood of Bausch Health, Inc. filing for bankruptcy before January 1, 2025, here are some key points to consider:\n\n## Current Denials of Bankruptcy Considerations\nBausch Health has explicitly denied reports that it is considering bankruptcy or insolvency proceedings. The company issued statements to this effect in response to rumors and a research report by Reorg[1][3][4].\n\n## Financial and Structural Challenges\nDespite the denials, Bausch Health faces significant financial and structural challenges. The company is in the process of separating its eye health business (B+L) through a spin-off, which could leave Bausch Health with an over-levered capital structure and a weak collection of supporting assets. This separation, if executed, would increase the probability of a medium-term bankruptcy filing[2].\n\n## Debt and Maturity Issues\nBausch Health has a complex debt structure and is facing significant debt maturities between 2025 and 2028. The company has attempted to reduce leverage through an exchange offer and open market repurchases of debt, but navigating these upcoming maturities remains challenging, especially if the company's key product, *Xifaxan*, faces generic competition[2].\n\n## Ongoing Discussions and Plans\nThere have been reports of ongoing discussions between Bausch Health and its creditors regarding a potential prepackaged Chapter 11 bankruptcy to restructure debt. However, these plans are not finalized, and the company has not confirmed these negotiations[5].\n\n## Base Rates and Reference Classes\nThe pharmaceutical industry, particularly companies with high leverage and pending major structural changes, has a higher risk profile for bankruptcy. However, the specific base rate for companies in Bausch Health's situation would need more detailed analysis.\n\n## Time to Resolution\nGiven the upcoming debt maturities and the ongoing discussions about potential restructuring, the time frame until January 1, 2025, is critical. Any significant financial stress or failure to address the debt issues could lead to a quicker resolution, either through restructuring or bankruptcy.\n\n### Conclusion\nWhile Bausch Health has denied considering bankruptcy, the company's financial situation and structural challenges suggest a heightened risk. The question of whether Bausch Health will file for bankruptcy before January 1, 2025, cannot be answered with certainty based on the current information. The outcome depends on various factors, including the success of the B+L separation, the company's ability to manage its debt, and the outcome of any ongoing restructuring discussions.\n\nRELEVANT SUBQUESTIONS:\n\nSUBQUESTION: Are any of Bausch Health's significant debt maturities due before January 1, 2025?\nANSWER: No, Bausch Health does not have any significant debt maturities due before January 1, 2025. According to the sources, there are no debt maturities until the fourth quarter of 2025[2][5].\n\n---\n\nSUBQUESTION: Has Bausch Health defaulted on any of its debt obligations as of today's date?\nANSWER: Based on the provided sources, there is no indication that Bausch Health has defaulted on any of its debt obligations as of the current date. Here are the key points:\n\n- The sources discuss various financial transactions, credit agreements, and debt ratings, but they do not mention any default on debt obligations[2][3][5].\n- Bausch Health has addressed market rumors about potential bankruptcy or insolvency, stating that such rumors are unsubstantiated[1].\n\nTherefore, based on the available information, the answer is:\n\nNO\n\n---\n\nSUBQUESTION: Are there reports of Bausch Health considering bankruptcy despite their public denials?\nANSWER: YES;\n\nThere were reports suggesting that Bausch Health was considering bankruptcy, despite the company's public denials. These reports originated from a research firm called Reorg, which stated that the company was negotiating a potential prepackaged Chapter 11 bankruptcy to address its debt issues[1][3][4].\n\nHowever, Bausch Health has categorically denied these rumors, stating that they are not considering any form of bankruptcy or insolvency proceedings[3][4][5].\n\n---\n\nSUBQUESTION: Has Bausch Health's credit rating been downgraded by major credit rating agencies recently?\nANSWER: No, Bausch Health's credit rating has not been downgraded recently by major credit rating agencies; instead, there have been some upgrades and affirmations.\n\n- S&P Global Ratings upgraded Bausch Health's issuer credit rating to 'CCC+' from 'CCC' and also raised its issue-level ratings on various debt instruments in April 2024[1].\n- Fitch Ratings affirmed Bausch Health's IDR at 'CCC' but did downgrade the second-lien and unsecured debt in November 2024[4].\n\nThese actions indicate changes but not a straightforward downgrade of the overall credit rating.\n\n---\n\nSUBQUESTION: Has Bausch Health completed the spin-off of its eye health business, Bausch + Lomb?\nANSWER: No, Bausch Health has not completed the full spin-off of its eye health business, Bausch + Lomb, although it has made significant progress. Here are the key points:\n\n- Bausch + Lomb was spun off and listed as a separate company in 2022, but Bausch Health retained an 88% stake in it[1][3][5].\n- There are ongoing efforts to complete the full spin-off, with Bausch Health working to refinance its debt to aid in this process[2][3].\n\nTherefore, while the initial separation has occurred, the full spin-off is still in the process of being completed.\n\n---\n\nSUBQUESTION: Is Bausch Health currently engaged in discussions with creditors about debt restructuring or bankruptcy plans?\nANSWER: Based on the provided sources, it is clear that Bausch Health is not currently engaged in discussions with creditors about bankruptcy plans.\n\n- A statement from Bausch Health explicitly denies considering bankruptcy or insolvency proceedings, and it was noted that the company has not been involved in discussions with its creditors regarding bankruptcy proceedings[3][5].\n\nHowever, the company has been involved in debt restructuring discussions and has rejected recent debt-restructuring proposals from bondholders. Bausch Health is working with Jefferies to explore refinancing some of its debt to aid a spinoff, but this does not involve bankruptcy plans[1][2].\n\nTherefore, the answer is:\n**NO**\n\n---\n\nSUBQUESTION: Is Bausch Health facing significant legal challenges affecting its key products, such as Xifaxan?\nANSWER: YES\n\nBausch Health is indeed facing significant legal challenges affecting its key product, XIFAXAN®. Here are the key points:\n\n- Bausch Health and its subsidiary, Salix Pharmaceuticals, have initiated a patent infringement case against Norwich Pharmaceuticals in June 2024, specifically over the generic version of XIFAXAN®[2][4].\n- Norwich Pharmaceuticals filed a Paragraph IV Certification notice with the FDA, challenging the validity of Bausch Health's XIFAXAN® patents, which led to the lawsuit[2][3].\n- The lawsuit involves allegations of patent infringement, violation of patent exclusivity, and potential market disruption due to Norwich’s plans to manufacture a generic version of XIFAXAN®[2].\n\nThese legal actions indicate ongoing and significant legal challenges for Bausch Health related to its key product, XIFAXAN®.\n\n---\n\nSUBQUESTION: Have other pharmaceutical companies with similar debt levels filed for bankruptcy in recent years?\nANSWER: Yes, several pharmaceutical and biotech companies with significant debt levels have filed for bankruptcy in recent years.\n\n- Companies like Achaogen, which filed for Chapter 11 bankruptcy in April 2019, and Insys Therapeutics, which filed for Chapter 11 bankruptcy in June 2019, are examples of this trend[2][5].\n- In 2023, companies such as Clovis Oncology, which was liquidated after a bankruptcy filing in December 2022, and Novan Therapeutics, which began selling its assets after bankruptcy, also faced financial distress[5].\n- More recently, in 2024, companies like Baudax Bio, which filed for Chapter 11 bankruptcy in February, and Impel Pharmaceuticals, which was sold to investors after bankruptcy, have also been affected[5].\n\nThese cases indicate that financial difficulties leading to bankruptcy are not uncommon in the pharmaceutical and biotech sectors.\n\n---\n\nSUBQUESTION: Is there evidence of declining revenue or profitability for Bausch Health in recent financial reports?\nANSWER: Based on the recent financial reports provided, there is no evidence of declining revenue for Bausch Health. Here are the key points:\n\n- The second quarter 2024 revenues were $2.40 billion, which is an 11% increase from the same quarter in 2023[2][3][4].\n- The first quarter 2024 revenues were $2.15 billion, also showing an 11% increase from the same quarter in the previous year[4][5].\n\nHowever, there are some indications of challenges in profitability:\n\n- The GAAP net income for Q2 2024 was $10 million, down from $26 million in Q2 2023, primarily due to higher interest expenses and lower operating income[3].\n- The GAAP EPS for Q2 2024 was $0.03, which is lower than the $0.07 in Q2 2023[3].\n\nTherefore, while revenue is increasing, there is evidence of a decline in certain profitability metrics such as GAAP net income and GAAP EPS.\n\n**YES** (for declining profitability in certain metrics)\n\n---\n\nSUBQUESTION: Is Bausch Health's stock price significantly lower compared to its value one year ago?\nANSWER: To determine if Bausch Health's stock price is significantly lower compared to its value one year ago, we need to compare the current stock price with the stock price from the same time last year.\n\nAs of November 18, 2024, the stock price of Bausch Health is approximately $8.48[3][5].\n\nLooking at the historical data, on November 12, 2023, the average stock price for Bausch Health was around $8.02, but for a more accurate comparison, we should consider the prices around the same period last year. The average stock price for 2023 was $7.8278, but specifically in November 2023, it was closer to the $8 range[4].\n\nHowever, to get a clearer picture, we can look at the specific dates:\n- On November 12, 2023, the stock price was around $8.02[4].\n- The 52-week high and low indicate significant fluctuations, but the current price is closer to the lower end of the range compared to the highs of the previous year[5].\n\nGiven that the stock price has been in a downtrend since 2000 and considering the recent prices, the current stock price of $8.48 is not significantly lower than the prices observed around the same time last year. Instead, it is relatively stable or slightly higher than some of the lower points in the last year.\n\nTherefore, the answer is:\n## NO",
    "comment": "(a) **Time left until the outcome is known**: Approximately **43 days** (from November 18, 2024, to January 1, 2025).\n\n---\n\n(b) **What the outcome would be if nothing changed**: If nothing changes, the outcome would be **No**—Bausch Health will not file for bankruptcy before January 1, 2025.\n\n---\n\n(c) **What I would forecast if there was only a quarter of the time left**: With about **11 days** left, I would forecast a probability of **2%** that Bausch Health will file for bankruptcy before the deadline.\n\n---\n\n(d) **What I would forecast if there was 4x the time left**: With approximately **172 days** (extending the deadline to around May 2025), I would increase the probability to **10%**.\n\n---\n\n**Rationale:**\n\n**Financial Position and Debt Obligations:**\n\n- **Debt Maturities:** Bausch Health has no significant debt maturities due before January 1, 2025. The next major debt obligations are due in Q4 2025. This reduces the immediate pressure to file for bankruptcy within the current time frame.\n- **Debt Restructuring Efforts:** The company is actively engaging in debt refinancing and has rejected recent debt-restructuring proposals from bondholders, indicating a willingness to manage debt without resorting to bankruptcy.\n\n**Operational Performance:**\n\n- **Revenue Growth:** Recent financial reports show that Bausch Health's revenues have increased by 11% in both Q1 and Q2 of 2024 compared to the same periods in the previous year.\n- **Profitability Challenges:** While revenues are increasing, GAAP net income and EPS have declined due to higher interest expenses and lower operating income. However, these declines have not resulted in defaults or immediate liquidity crises.\n\n**Legal Challenges:**\n\n- **Xifaxan Litigation:** Bausch Health is involved in ongoing patent litigation concerning its key product, Xifaxan. Although significant, the legal proceedings are unlikely to compel a bankruptcy filing within the next 43 days.\n\n**Market Indicators:**\n\n- **Stock Price Stability:** The stock price is relatively stable compared to its value one year ago, suggesting that investors are not anticipating an imminent bankruptcy.\n- **Credit Ratings:** Recent actions by credit rating agencies have included upgrades and affirmations, not downgrades. S&P Global Ratings upgraded Bausch Health in April 2024.\n\n**Company Statements:**\n\n- **Denial of Bankruptcy Plans:** Bausch Health has publicly denied considering bankruptcy or insolvency proceedings and is not in discussions with creditors about bankruptcy plans.\n- **Spin-off Progress:** The company has made significant progress in spinning off its eye health business, Bausch + Lomb, retaining an 88% stake. Completion of this spin-off could improve the capital structure.\n\n**Base Rates and Industry Context:**\n\n- **Industry Base Rates:** While highly leveraged pharmaceutical companies face higher bankruptcy risks, the probability of filing within a 43-day window without triggering events is low.\n- **Comparable Cases:** Other pharmaceutical companies have filed for bankruptcy due to significant debt and operational failures, but these often follow prolonged distress and defaults.\n\n**Time Frame Considerations:**\n\n- **Short-Term Outlook:** With only 43 days left, and no immediate catalysts or deadlines prompting bankruptcy, the likelihood is low.\n- **Extended Time Frame:** If the time frame were extended (e.g., 4x the time), risks associated with debt maturities and legal challenges could become more pressing, slightly increasing the probability.\n\n**Conclusion:**\n\nGiven the absence of immediate debt maturities, stable revenues, proactive financial management, and short time frame until January 1, 2025, the probability of Bausch Health filing for bankruptcy before the deadline is low.\n\n---\n\n**Probability: 5%**",
    "probability": 5
}